HuidaGene Therapeutics ("HuidaGene"), a global clinical-stage biotechnology company pioneering CRISPR-based programmable genome medicines, today announced the appointment of Dr. TJ Cradick as Chief ...
A study reveals that CRISPR gene editing can disable a mutation in melanoma cells that leads to treatment resistance. By targeting the NRAS gene mutation, researchers restored the cells' sensitivity ...